Citadel Advisors
ACET icon

Citadel Advisors’s Adicet Bio ACET Stock Holding History

Citadel Advisors’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,700
Closed -$16.6K – 12631
2025
Q2 		$16.6K Sell
1,700
-606
-26% -$6.39K ﹤0.01% 12140
2025
Q1 		$27.9K Buy
2,306
+1,850
+406% +$26.5K ﹤0.01% 12890
2024
Q4 		$7.02K Buy
456
+193
+73% +$3.64K ﹤0.01% 13763
2024
Q3 		$6.05K Sell
263
-6
-2% -$134 ﹤0.01% 13447
2024
Q2 		$5.2K Sell
269
-562
-68% -$15.1K ﹤0.01% 13425
2024
Q1 		$31.3K Buy
831
+725
+684% +$30K ﹤0.01% 12662
2023
Q4 		$3.21K Sell
106
-57
-35% -$1.24K ﹤0.01% 13617
2023
Q3 		$3.56K Sell
163
-462
-74% -$16.3K ﹤0.01% 13571
2023
Q2 		$24.3K Sell
625
-813
-57% -$71.8K ﹤0.01% 12563
2023
Q1 		$132K Sell
1,438
-131
-8% -$16.4K ﹤0.01% 10837
2022
Q4 		$224K Buy
1,569
+919
+141% +$229K ﹤0.01% 9910
2022
Q3 		$148K Sell
650
-969
-60% -$246K ﹤0.01% 10709
2022
Q2 		$378K Buy
+1,619
New +$356K ﹤0.01% 9269
2022
Q1 		– Sell
-1,206
Closed -$338K – 13456
2021
Q4 		$338K Buy
+1,206
New +$207K ﹤0.01% 10660

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors's ACET Position: Q1 2026 in Review

Citadel Advisors increased its Adicet Bio (ACET) stake by 254% in Q1 2026, buying an estimated $2.05M and bringing the position to 381,823 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #5540.

Citadel Advisors first reported a position in ACET in Q1 2018 and has held it in 21 quarters since. The position peaked at $3.72M in Q3 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Citadel Advisors held 381,823 shares of Adicet Bio worth $2.6M as of Q1 2026.
  • Citadel Advisors bought 274,009 Adicet Bio shares in Q1 2026, an estimated $2.05M.
  • Adicet Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5540 holding.
  • Citadel Advisors first reported a position in Adicet Bio in Q1 2018 and has held it in 21 quarters since.
  • Citadel Advisors's Adicet Bio position peaked at $3.72M in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.